ORBIMED ADVISORS LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.45B2026 Q3+ $45.7M options (notional, not included)
Positions124
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.48.7%

ORBIMED ADVISORS LLC reported 124 positions worth $5.45B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: EWTX (11.5%). Biggest move: new buy ADRX ($482.7M).

10 / 124 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 EWTXEdgewise Therapeutics$630.1M11.46%15,518,492——+7.6%
▸ 2 ADRXADARx Pharmaceuticals$482.7M8.78%24,205,789——-28.8%
▸ 3 ELVNEnliven Therapeutics$310.6M5.65%6,776,632——+3.9%
▸ 4 LLYEli Lilly$298.4M5.43%257,900——+23.7%
▸ 5 BRVEBraveheart Bio$245.9M4.47%12,175,159——-2.9%
▸ 6 SVASinovac Biotech$195.5M3.56%2,718,735———
▸ 7 MBXMBX Biosciences$180.2M3.28%3,074,853——-9.4%
▸ 8 MRKMerck$137.5M2.50%946,100——-0.6%
▸ 9 GHGuardant Health$104.2M1.89%584,100——-19.2%
▸ 10 AVBPArriVent BioPharma$91.7M1.67%3,027,328——-57.0%

Pro Feature

The remaining 114 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does ORBIMED ADVISORS LLC hold as of Q3 2026?

ORBIMED ADVISORS LLC reported 124 positions worth $5.45B in its Q3 2026 13F filing. Largest positions: EWTX (11.5%), ADRX (8.8%), ELVN (5.6%), LLY (5.4%) and BRVE (4.5%).

What did ORBIMED ADVISORS LLC buy in Q3 2026?

New positions: ADRX, BRVE, ETRA, TNGX and ABBV (33 in all). Added to: TVTX, MRK, ARQT, ASND and UNH (18 in all).

What did ORBIMED ADVISORS LLC sell in Q3 2026?

Reduced: AZN, ABVX, GPCR, NTRA and ISRG (36 in all). Sold out entirely: DYN, CGON, BSX, XENE and BMY (38 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.